Autres langues AstraZeneca PLC Deutsche Boerse AG

Actions

ZEG

GB0009895292

Produits pharmaceutiques

Temps réel estimé Tradegate 17:48:34 05/10/2026			Varia. 5j.	Varia. 1 janv.
138,82 ^EUR	-1,12%		-6,14%	-12,07%

14:22	AstraZeneca finalise un investissement de 2 milliards d'euros
13:54	AstraZeneca finalise un investissement de 2 milliards de dollars US dans Summit	AN

Autres langues

17:01	Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
13:54	AstraZeneca completes USD2 billion Summit investment
13:40	Summit Therapeutics Secures $2 Billion Investment From AstraZeneca
13:28	AstraZeneca Finalizes $2 Billion Investment in Summit Therapeutics
02/10	AbbVie joins US government pilot to test drug discount rebates
02/10	Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion
02/10	AstraZeneca PLC, Daiichi Sankyo And Summit Therapeutics Inc. Announce Clinical Collaboration To Evaluate Datroway In Combination With Ivonescimab Across Multiple Tumour Types
02/10	Novartis strikes up to $7.8 billion mRNA deal with China's Abogen
02/10	Major drugmakers turn to China for licensing deals
02/10	AstraZeneca, Daiichi Sankyo to Evaluate Datroway Combo Across Tumor Types with Summit Therapeutics
02/10	Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway(R) in Combination with Ivonescimab Across Multiple Tumor Types
02/10	Daiichi, AstraZeneca enter clinical trial cooperation with Summit
02/10	Japanese Stocks Fall as Global Bond Sell-Off Drives Borrowing Costs; Oil Rises
02/10	Daiichi Sankyo, AstraZeneca to Test Datroway-Ivonescimab Combo for Breast Cancer Treatment
02/10	AstraZeneca, Daiichi Sankyo, Summit Therapeutics Partner Test Cancer Drug Combination
02/10	AstraZeneca, Daiichi Sankyo, Summit Therapeutics to Collaborate on Cancer Combination Therapy Trials
02/10	AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination
02/10	UK Stocks-Factors to watch on October 2
30/09	Weight-loss drug developers line up to tap lucrative market as competition heats up
30/09	Major drugmakers turn to China for licensing deals
30/09	Dizal Gets Initial $600 Million in Licensing Fees from AstraZeneca for Cancer Drug
29/09	AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says
29/09	European Equities Decline in Tuesday Trading; BlackRock, Vanguard Face Pressure as European Banks Launch ETFs
29/09	British Shares End Lower Amid Credit, Shop Price Inflation Reports; Vesuvius Surges
29/09	Global markets live: Nvidia, Meta, Anthropic, OpenAI, Boeing…